Aeterna Zentaris (NASDAQ: AEZS) shares are higher after the company this morning said that is has resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Macrilen™ for the evaluation of growth hormone deficiency in adults (AGHD). The resubmission comes ahead of the company’s previously announced schedule, and the company anticipates an FDA review period of six months. “We anticipate successful FDA approval and, as a result, we continue to build our commercial organization and infrastructure in preparation for the earliest possible launch of Macrilen™. Our focus is to be prepared to launch the product in the first quarter of 2018,” Aeterna Zentaris president and CEO David A. Dodd stated in the news release.
To view the full press release, visit: http://nnw.fm/2Qc6H
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. The company is engaged in drug development activities and in the promotion of products for others. Aeterna recently completed phase 3 studies of two internally developed compounds. The focus of the business development efforts is the acquisition of licenses to products that are relevant to Aeterna’s therapeutic areas of focus. The company also intends to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable Aeterna to ensure development, registration and launch of its product candidates. The company’s goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of its product portfolio, achieving successful commercial presence and growth, while consistently delivering value to its shareholders, employees and the medical providers and patients who will benefit from these products. For more information, visit www.aezsinc.com.
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer